[(1E,7E,9E,11E)-3,6,13-trihydroxy-3-methyl-1-(6-oxo-2,3-dihydropyran-2-yl)trideca-1,7,9,11-tetraen-4-yl] dihydrogen phosphate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡喃
• 英文名称: [(1E,7E,9E,11E)-3,6,13-trihydroxy-3-methyl-1-(6-oxo-2,3-dihydropyran-2-yl)trideca-1,7,9,11-tetraen-4-yl] dihydrogen phosphate
• 化学式: C₁₉H₂₇O₉P
• 分子量: 430.4
• InChiKey: ZMQRJWIYMXZORG-CVMFKEHVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  29
• 可旋转键数：
  11
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  154
• 氢给体数：
  5
• 氢受体数：
  9

文献信息

• Pyranones and related compounds and methods for their production and use
  申请人：WARNER-LAMBERT COMPANY

  公开号：EP0128651A2

  公开（公告）日：1984-12-19

  This invention relates to a compound in substantially pure form, selected from: (a) alcohols having the following structural formulae 1 a, 1 b and 1c: where for 1 a, R1 = H, and R2 = OH, for 1b, R1 = R2 = H, and for 1c, R1 = R2 = OH; (b) phosphates having the following structural formulae 2a, 2b, and 2c: where for 2a, R1 = H, and R2 = OH, for 2b, R1 = R2 = H, and for 2c, R1 = R2 = OH; (c) esters of the phosphate function of the phosphates of (b) and further pyranone phosphates designated CL 1565-A, CL 1565-B, and CL 1565-T having the following structural formulae 3a, 3b, and 3c, respectively: where for 3a, R' = H, and R2 = OH, for 3b, R1 = R2 = H, and for 3c, R1 = R2 = OH; (d) acyl esters of the alcohols of (a) and of the pyranone phosphates of (c); (e) the compound designated CL 1565-PT-3; and (f) the pharmaceutically acceptable salts of the phosphates of (b), the pyranone phosphate esters of (c), the pyranone acyl esters of (d), and CL 1565-PT-3. The invention also provides for the production of such compounds. The compounds possess anti-tumor activity.

  本发明涉及一种基本纯净的化合物，选自以下物质： (a) 具有下列结构式 1a、1b 和 1c 的醇： 其中，对于 1a，R1 = H，R2 = OH、 对于 1b，R1 = R2 = H，以及 1c 中，R1 = R2 = OH； (b) 具有以下结构式的磷酸盐： 2a、2b 和 2c： 对于 2a，R1 = H，R2 = OH、 对于 2b，R1 = R2 = H，以及 对于 2c，R1 = R2 = OH； (c) (b)的磷酸酯的磷酸酯官能团，以及进一步的吡喃酮磷酸酯，命名为 CL 1565-A、CL 1565-B 和 CL 1565-T，其结构式分别为 3a、3b 和 3c： 对于 3a，R' = H，R2 = OH、 对于 3b，R1 = R2 = H，以及 对于 3c，R1 = R2 = OH； (d) (a)的醇和(c)的吡喃酮膦酸酯的酰基酯； (e) 定名为 CL 1565-PT-3 的化合物；以及 (f) (b)的磷酸酯、(c)的吡喃酮磷酸酯、(d)的吡喃酮酰基酯和 CL 1565-PT-3 的药学上可接受的盐。 本发明还提供了此类化合物的生产方法。 这些化合物具有抗肿瘤活性。
• Binding molecules and methods of use thereof
  申请人：Cuervo H. Julio

  公开号：US20070248988A1

  公开（公告）日：2007-10-25

  Binding molecules are described.
• Altered polypeptides, immunoconjugates thereof, and methods related thereto
  申请人：van Vlijmen Herman

  公开号：US20090258420A1

  公开（公告）日：2009-10-15

  The present invention features inter alia altered binding polypeptides having engineered cysteine residues or analogs thereof at a predetermined site within, for example, a constant region domain or a portion thereof. The engineered cysteine residues or analogs thereof provide sites for conjugating effector moieties (e.g. diagnostic or therapeutic agents) that impart novel functionality to the binding polypeptide, preferably without interfering with a desirable property (e.g. an Fc-mediated effector function). The invention includes methods for the rational design of such altered polypeptides, as well as methods for modifying (ie. conjugating) the altered polypeptides with desirable effector moieties. Particular modified binding polypeptides (ie. immunoconjugates) of altered binding polypeptides and methods for utilizing such modified binding polypeptides as protein-based therapeutics are also provided.
• US4680416A
  申请人：——

  公开号：US4680416A

  公开（公告）日：1987-07-14